Saudi biotech startup Novo Genomics signed two major agreements: one with Tracer Biotechnologies to localize ctDNA monitoring ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $482.4, with a high estimate of $567.00 and a low estimate of $420.00. This current average ...

Major global pharmaceutical companies traded lower in the premarket on Tuesday after President Donald Trump reiterated his ...

Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company ...

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...

The deal centers around a medicine that could “shift the treatment paradigm for cardiovascular disease,” Lilly said, but also ...

Eli Lilly (LLY) will acquire Verve Therapeutics (VERV) for up to $13.5/share, aiming to revolutionize cholesterol treatment.

Eli Lilly agreed to acquire Verve Therapeutics for approximately $1 billion up front, adding a potential treatment for ...

Aries Wealth Management has tiptoed into biotech by acquiring 605 shares of Vertex Pharmaceuticals, valued around $293,000. Other hedge funds also took notice, adjusting their positions during the ...